Cesca Therapeutics To Announce Financial Results For The Third Quarter Ended September 30, 2018 And Host Conference Call On November 14
RANCHO CORDOVA, Calif., Nov. 7, 2018 /PRNewswire/ -- Cesca Therapeutics Inc. ("Cesca" or the "Company") (NASDAQ: KOOL), a market leader in automated cell processing and point-of-care, autologous cell-based therapies, today announced that the Company will release its financial results for the third quarter ended September 30, 2018 on Wednesday, November 14, 2018 after the close of trading. A conference call and webcast will follow at 4:30 p.m. EST (1:30 p.m. PST).
Participants may access the call by dialing 1-844-889-4331 within the U.S. or 1-412-380-7406 outside the U.S. and referencing "Cesca." To access a live webcast of the call, please visit: https://services.choruscall.com/links/kool181113.html.
A replay of the call will be available until December 4, 2018 and can be accessed by dialing 1-877-344-7529 within the U.S. or 1-412-317-0088 outside the U.S. and referencing access code 10125285.
About Cesca Therapeutics Inc.
Cesca Therapeutics Inc. (the "Company") develops, commercializes and markets a range of automated technologies for CAR-T and other cell-based therapies. Its device division, ThermoGenesis Corp., provides a full suite of solutions for automated clinical biobanking, point-of-care applications, and automation for immuno-oncology. The Company is developing an automated, functionally-closed CAR-TXpress™ platform to streamline the manufacturing process for the emerging CAR-T immunotherapy market. For additional information, please go to: http://www.cescatherapeutics.com.
Company Contact:
Cesca Therapeutics Inc.
Wendy Samford
916-858-5191
ir@cescatherapeutics.com
Investor Contact:
Rx Communications
Paula Schwartz
917-322-2216
pschwartz@rxir.com
View original content:http://www.prnewswire.com/news-releases/cesca-therapeutics-to-announce-financial-results-for-the-third-quarter-ended-september-30-2018-and-host-conference-call-on-november-14-300744989.html
SOURCE Cesca Therapeutics Inc.
